DEC 26, 2018 8:13 PM PST

When the Immune System Makes a Mistake: Autoimmunity

WRITTEN BY: Nicholas Breehl

A team from Scripps Research has found a molecular cause of a group of rare autoimmune disorders in which the immune system attacks the body's healthy cells.


The discovery, published Dec. 18 in Nature Communications, improves understanding of a protein's role in several autoimmune disorders, including Singleton-Merten syndrome (SMS), Aicardi-Goutières syndrome, familial chilblain lupus, proteasome-associated autoinflammatory syndromes and many others which involve improper stimulation of interferon, says Patrick Griffin, PhD, professor and co-chair of the Department of Molecular Medicine at Scripps Research's Florida campus.


Interferon is a critical component of our frontline defense against pathogens. Interferon earned its name because it interferes with virus' ability to make copies of themselves. The immune system relies on a gene called RIG-I, short for retinoic acid-inducible gene-I, to signal for the release of interferon whenever specific viral markers are encountered. RIG-I has to determine if the markers are of foreign origin or are from its own body. The scientists demonstrated precisely how mistakes in a molecular proofreading system could lead to confusion and generate out-of-control interferon signaling, setting off development of autoimmune disease.


"This dysregulated molecular mechanism of RIG-I mediated RNA proofreading that we identified may help us understand and treat SMS and other autoimmune disorders," says Jie Zheng, Ph.D., a postdoctoral associate and the first author and co-corresponding author of the study.


The National Institutes of Health estimates more than 20 million Americans suffer from autoimmune disorders. They include rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, lupus, type 1 diabetes, and dozens of others. There are very few safe and effective treatments for such disorders, mainly because so little is understood about how they arise and are sustained.


That is true for SMS, which is so rare that only a few cases have been described in the medical literature. Patients develop serious bone, heart, muscle and skin problems starting in early childhood, primarily due to chronic inflammation from an overactive immune system. The scientists aimed to understand how two RIG-I mutations linked to SMS end up triggering the autoimmunity.


Most viruses have genes made of ribonucleic acid, or RNA, a close chemical cousin of DNA. RIG-I works as an early-warning detector of viral RNA, capable of triggering a broad antiviral immune response, including interferon release. The scientists showed that mutations in RIG-I cause the sensor protein to activate even when it encounters non-viral, "self" RNA. The study aimed to discover the molecular details of how this happens.


RIG-I is a significant protein with flexible elements, and thus is hard to study with standard techniques. But Griffin has helped pioneer the use of an advanced technology called hydrogen-deuterium exchange mass spectrometry (HDX-MS), which enables scientists to analyze the structures and dynamics of just such proteins. For the study, he and his team applied HDX-MS to normal and mutant RIG-I and permanently solved the mystery of how these mutations cause a failure of discrimination between self and viral RNA.


Scientists have known that RIG-I has a particular segment that it keeps mostly covered and concealed. When RIG-I encounters and recognizes viral RNA, this segment is supposed to briefly swing open and thus become available for binding to another protein called MAVS, an event that triggers the immune response. Griffin and colleagues found that the two SMS-linked mutations, in subtly different ways, cause this critical segment of RIG-I to become stuck open -- making it much more likely to bind to MAVS and trigger an immune response.


The scientists now are using their data to try to find a way to target mutant RIG-I, to block its inappropriate signaling to MAVS and thus alleviate the autoimmunity it causes.


This new, detailed understanding of RIG-I's dysfunction may not only provide insights into the origins of more common autoimmune disorders, Griffin says, but it also clarifies how RIG-I usually works to detect viruses, a discovery that may enable development of new antiviral drugs.

Sources: Science Daily, Nature Communications, YouTube

About the Author
You May Also Like
JUL 30, 2020
Genetics & Genomics
How Are DNA Testing Companies Helping the Fight Against COVID?
JUL 30, 2020
How Are DNA Testing Companies Helping the Fight Against COVID?
One of the most puzzling characteristics of coronavirus is how some people develop severe symptoms and die from the dise ...
OCT 05, 2020
Immunology
Can't Shed Those Extra Pounds? An Inflammatory Gene Could Be to Blame.
OCT 05, 2020
Can't Shed Those Extra Pounds? An Inflammatory Gene Could Be to Blame.
  Australian scientists have zeroed in on a gene linked to an increased obesity risk: a regulator of inflammation c ...
OCT 21, 2020
Immunology
CNS's immune cells - Microglia are involved in the exacerbation of MS
OCT 21, 2020
CNS's immune cells - Microglia are involved in the exacerbation of MS
Multiple sclerosis (MS) is one of the most progressive autoimmune diseases that affect the central nervous system where ...
OCT 24, 2020
Immunology
New CRISPR-Based Imaging Tool Is Going to Be HiUGE
OCT 24, 2020
New CRISPR-Based Imaging Tool Is Going to Be HiUGE
A team of researchers at Duke University have developed an imaging technology for tagging structures at a cellular level ...
NOV 04, 2020
Coronavirus
Damaging Antibodies Can Lead to Blood Clots in COVID-19 Patients
NOV 04, 2020
Damaging Antibodies Can Lead to Blood Clots in COVID-19 Patients
COVID-19, the illness caused by the pandemic virus SARS-CoV-2, is known to cause blood clots all over the body in some p ...
NOV 16, 2020
Immunology
Australian COVID-19 vaccine is promising and could be released next year
NOV 16, 2020
Australian COVID-19 vaccine is promising and could be released next year
Pharmaceutical companies worldwide are racing to develop a COVID-19 vaccine that will hopefully end this pandemic and he ...
Loading Comments...